Get information about the importance of screening for depression and talking to your primary care provider (PCP) if you think you might be suffering from depression.
David Mischoulon, MD, PhD
David Mischoulon, MD, PhD
Director, Depression Clinical and Research Program
Departments, Centers, & Programs:
Mass General Psychiatry: Depression Clinical & Research Program
One Bowdoin Square
Boston, MA 02114
- PhD, Boston University School of Medicine
- MD, Boston University School of Medicine
- Residency, Massachusetts General Hospital
American Board Certifications
- Psychiatry, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Since March 2017, I have served as the Director of the MGH Depression Clinical and Research Program, where I mentor our program’s approximately 15 faculty psychiatrists and psychologists. My research interests focus on complementary and alternative medicine (CAM) in psychiatry. I have been successful in obtaining funding to support my research since the completion of my residency in 1998. From 1998-2002, I was funded by two consecutive Young Investigator award from the National Association for Research on Schizophrenia and Depression (NARSAD); the first project examined folate metabolism abnormalities in depression, and the second project examined the omega-3 docosahexaenoic acid (DHA) as a potential antidepressant. In 2001, I received a K-23 award from the National Center for Complementary and Alternative Medicine (NCCAM) to study another omega-3, eicosapentaenoic acid (EPA), for treating depression. This work led to my receiving a collaborative R01 grant (MGH and Emory University) from the National Institutes of Health (NIH) in 2006, for a clinical trial comparing EPA vs. DHA for depression. In 2015, I obtained a UG3 grant, again in collaboration with Emory University, to continue my work on omega-3s as a treatment for overweight individuals with depression and elevated inflammation, a potential step toward a niche for CAM as a form of personalized medicine. My research publications also include reports of studies of treatment of depression in patients with alcohol use disorders, atypical antipsychotics as adjunctive therapies for depression, and treatment of depression in minorities.
Related News and Articles
- Patient Education
- Jan | 21 | 2021
With recommendations to stay at home this winter to help stop the spread of COVID-19, David Mischoulon, MD, PhD, offers insights on SAD and how to stay well at home this winter.